{"id":"ads-5102","safety":{"commonSideEffects":[{"rate":null,"effect":"Hallucinations"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Peripheral edema"}]},"_chembl":{"chemblId":"CHEMBL603031","moleculeType":"Small molecule","molecularWeight":"422.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ADS-5102 delivers amantadine in an extended-release formulation designed to maintain therapeutic levels throughout the day. Amantadine works through multiple mechanisms including NMDA receptor antagonism and dopamine agonism, which help reduce dyskinesia and other movement disorders by modulating glutamatergic and dopaminergic neurotransmission in the basal ganglia.","oneSentence":"ADS-5102 is an extended-release formulation of amantadine that provides sustained dopaminergic and anti-glutamatergic activity to reduce involuntary movements.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:01.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Levodopa-induced dyskinesia in Parkinson's disease patients"}]},"trialDetails":[{"nctId":"NCT03567057","phase":"PHASE3","title":"A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment","status":"COMPLETED","sponsor":"Adamas Pharmaceuticals, Inc.","startDate":"2018-07-18","conditions":"Multiple Sclerosis, Walking Impairment","enrollment":424},{"nctId":"NCT03436199","phase":"PHASE3","title":"Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment","status":"COMPLETED","sponsor":"Adamas Pharmaceuticals, Inc.","startDate":"2018-03-29","conditions":"Walking Impairment, Multiple Sclerosis","enrollment":558},{"nctId":"NCT02202551","phase":"PHASE3","title":"Open-Label Safety Study of ADS-5102 in PD Patients With LID","status":"COMPLETED","sponsor":"Adamas Pharmaceuticals, Inc.","startDate":"2014-07","conditions":"Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease (PD)","enrollment":223},{"nctId":"NCT02136914","phase":"PHASE3","title":"ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)","status":"COMPLETED","sponsor":"Adamas Pharmaceuticals, Inc.","startDate":"2014-05","conditions":"Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease","enrollment":126},{"nctId":"NCT02274766","phase":"PHASE3","title":"Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia","status":"COMPLETED","sponsor":"Adamas Pharmaceuticals, Inc.","startDate":"2014-10","conditions":"Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)","enrollment":77},{"nctId":"NCT01397422","phase":"PHASE2, PHASE3","title":"Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)","status":"COMPLETED","sponsor":"Adamas Pharmaceuticals, Inc.","startDate":"2011-07","conditions":"Dyskinesia, Levodopa Induced Dyskinesia, Parkinson's Disease","enrollment":83},{"nctId":"NCT02471222","phase":"PHASE2","title":"Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment","status":"COMPLETED","sponsor":"Adamas Pharmaceuticals, Inc.","startDate":"2015-05","conditions":"Walking Impairment, Multiple Sclerosis","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["amantadine HCl extended release"],"phase":"phase_3","status":"active","brandName":"ADS-5102","genericName":"ADS-5102","companyName":"Adamas Pharmaceuticals, Inc.","companyId":"adamas-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ADS-5102 is an extended-release formulation of amantadine that provides sustained dopaminergic and anti-glutamatergic activity to reduce involuntary movements. Used for Levodopa-induced dyskinesia in Parkinson's disease patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}